Glaxo keeps Ebola vax manufacturing in-house; 'Anti-typhoid' gene could improve vaccines;

> GlaxoSmithKline ($GSK) is keeping its Ebola vaccine production in-house. Report

> Scientists have found a gene variant that may provide better protection against typhoid fever. Report

> VaxInnate's quadrivalent seasonal influenza vaccine candidate has met its Phase I endpoints. Release

> Malaysian biotech Sentinext Therapeutics has successfully completed a $14 million Series B financing round that will take its hand, foot and mouth disease vaccine into Phase I clinical trials. More

> Abivax has inked a pact with the Finlay Institute to commercialize meningococcal and typhoid vaccines in Asia and Latin America. Release

> Malaria vaccine maker SutroVax is in search of Series A funding. More

And Finally... Unused flu vaccine costs California $1 million each year. More